The authors also showed that these STAT5BN642H mutation mice could be successfully treated with ruxolitinib, a JAK inhibitor, further emphasizing the central role of dysregulated STAT signaling in LGLL pathogenesis (78). Here, SOAT1 is linked to T-cell large granular lymphocyte leukemia.